RESUMEN
Herein we report a rare case of disseminated herpes zoster(HZ) infection involving two widely separated bilateral dermatomes in an immunocompetent host. HZ involving two widely separated areas simultaneously is referred to as HZ duplex bilateralis. It is very rare, with an incidence of less than 0.1 percent of all HZ cases, and usually develops in immunocompromised patients.
Asunto(s)
Herpes Zóster/tratamiento farmacológico , Aciclovir/administración & dosificación , Aciclovir/análogos & derivados , Antivirales/administración & dosificación , Herpes Zóster/sangre , Herpes Zóster/patología , Humanos , Masculino , Persona de Mediana Edad , Valaciclovir , Valina/administración & dosificación , Valina/análogos & derivadosRESUMEN
Cutaneous angiosarcoma (CAS) is a rare soft-tissue sarcoma of vascular endothelial origin. Paclitaxel (PTX) and docetaxel (DTX) are used as systemic chemotherapy; however, chemoresistance often occurs in CAS. Switching one taxane to the other (i.e., PTX to DTX, or vice versa) is an option when the first taxane is no longer effective in malignant cancers such as ovarian or breast cancer. However, the efficacy of the same strategy in CAS has not been reported. Herein, we report the clinical response of switching one taxane-based chemotherapy to the other in CAS patients with resistance to the first taxane. Twelve CAS patients were included for analyses. In all patients, the median overall survival from the start of the first taxane treatment was 29.0 months (range, 6.47-58.5). During the first taxane, the median PFS for all patients was 5.96 months (1.81-47.1). Similarly, the median (range) PFS for all patients during the second taxane was 5.87 months (1.60-18.2). Furthermore, the median OS was 22.7 months (PTX to DTX) and 39.5 months (DTX to PTX) (p = 0.307). The median PFS during the first taxane was 5.14 (PTX to DTX) and 12.5 months (DTX to PTX), respectively (p = 0.380). The median PFS during the second taxane was 3.5 (PTX to DTX) and 7.1 months (DTX to PTX), respectively (p = 0.906). The objective response rate, defined as the sum of complete response (CR) and partial response (PR) rates, was 16.7%. The disease control rate, defined as the sum of CR, PR, and stable disease rates, was 50%. The frequency of adverse events during the second taxane was the same between the two groups (p > 0.999). Our report suggests that CAS patients could benefit from the second taxane treatment if the tumor is resistant to the first taxane.
Asunto(s)
Hemangiosarcoma , Neoplasias Cutáneas , Humanos , Paclitaxel/uso terapéutico , Docetaxel/uso terapéutico , Hemangiosarcoma/tratamiento farmacológico , Hemangiosarcoma/etiología , Taxoides/uso terapéutico , Neoplasias Cutáneas/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéuticoRESUMEN
This paper reports a case of adult HFMD with vesicles scattered on the whole body and severe oral lesions. In addition, a long-lasting elevated level of C-reactive protein (CRP) was a feature of this case. Our case is unusual for HFMD with long-lasting joint pain and high fever.
Asunto(s)
Artritis/diagnóstico , Fiebre/diagnóstico , Enfermedad de Boca, Mano y Pie/diagnóstico , Adulto , Artritis/etiología , Proteína C-Reactiva/análisis , Fiebre/etiología , Enfermedad de Boca, Mano y Pie/complicaciones , Humanos , Masculino , Índice de Severidad de la EnfermedadRESUMEN
Pseudoxanthoma elasticum (PXE) is a progressive hereditary disease that affects tissues such as the skin, retina, blood vessels, and gastrointestinal tracts. Therefore, comprehensive medical care across clinical departments specialized in specific organs is needed to provide the best clinical practices to PXE patients. The Japanese version of clinical guidelines developed by the Japanese Dermatological Association was published in 2017, and aimed to promote equal accessibility of PXE-related medical care. Here, the English version of Japanese guideline is reported, and is intended to be worldwide reference for medical care of PXE.
Asunto(s)
Seudoxantoma Elástico , Humanos , Guías de Práctica Clínica como Asunto , Seudoxantoma Elástico/diagnóstico , Seudoxantoma Elástico/genética , Seudoxantoma Elástico/terapia , Retina , PielAsunto(s)
Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Neoplasias Cardíacas/inmunología , Linfocitos Infiltrantes de Tumor/inmunología , Micosis Fungoide/inmunología , Neoplasias Cutáneas/inmunología , Adulto , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/análisis , Biopsia , Trasplante de Células Madre de Sangre del Cordón Umbilical , Neoplasias Cardíacas/secundario , Neoplasias Cardíacas/terapia , Humanos , Inmunohistoquímica , Inmunofenotipificación , Metástasis Linfática , Masculino , Micosis Fungoide/sangre , Micosis Fungoide/patología , Micosis Fungoide/terapia , Estadificación de Neoplasias , Fenotipo , Neoplasias Cutáneas/sangre , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapiaRESUMEN
Pachydermoperiostosis (PDP) is a genetic disease characterized by digital clubbing, periostosis, and pachydermia caused by mutated HPGD or SLCO2A1. Plasma prostaglandin (PG)E2 levels are increased in these patients. However, other eicosanoids have not been quantitated. We aimed to quantitate plasma eicosanoid levels in four patients carrying SLCO2A1 mutations by high-performance liquid chromatography-tandem mass spectrometry. PGE2 level was elevated in all patients; PGD2 and 11ß-PGF2 α levels were also increased in some patients, whereas eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid levels were decreased in all patients. Our data indicate a dysfunctional eicosanoid homeostasis and varied levels of PG in patients with a complete form of PDP carrying SLCO2A1 mutations. PGE2 levels seem to mostly affect the symptoms, with other eicosanoids possibly having a minor effect.
Asunto(s)
Transportadores de Anión Orgánico , Osteoartropatía Hipertrófica Primaria , Dinoprostona , Eicosanoides , Humanos , Mutación , Transportadores de Anión Orgánico/genética , Osteoartropatía Hipertrófica Primaria/diagnóstico , Osteoartropatía Hipertrófica Primaria/genéticaAsunto(s)
Dermatitis Alérgica por Contacto/etiología , Desinfectantes/efectos adversos , Dispositivos de Protección Respiratoria/efectos adversos , Urticaria/etiología , Infecciones Bacterianas/prevención & control , Dermatitis Alérgica por Contacto/fisiopatología , Dermatosis Facial/etiología , Dermatosis Facial/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Máscaras/efectos adversos , Persona de Mediana Edad , Pruebas del Parche , Urticaria/fisiopatologíaRESUMEN
We describe a 53-year-old man with a two-year history of bullous disease. He had also had stage IV gastric cancer for 3 years. He presented with cutaneous erythemas and blisters, showing an annular arrangement. Histopathological examination revealed intraepidermal pustules of eosinophils and neutrophils without apparent acantholysis. Indirect immunofluorescence (IIF) analysis showed IgG anti-keratinocyte cell surface antibodies. The result of IIF on rat bladder was positive. IgG enzyme-linked immunosorbent assays failed to detect antibodies to either anti-desmoglein-1 (Dsg1), Dsg3, or BP180. Immunoblot analysis with normal human epidermal extract revealed IgG reactivity with 120, 110, and 100 kDa species. Immunofluorescence analysis using COS-7 cells that expressed desmocollin (Dsc) 1, 2, and 3 demonstrated that IgG autoantibodies in the patient's serum reacted with all Dsc1-3. A heterogeneous autoantibody profile including IgG reactivity against Dsc1-3 implicated association with cancer-related pemphigoid, although the findings did not fulfill the diagnostic criteria of paraneoplastic pemphigus. A review of the literature revealed that rare autoantibodies to Dsc, most of which were IgA class, were detected in 7 reported bullous diseases. In 5 out of 7 cases, they were combined with autoantibodies to bullous pemphigoid or pemphigus vulgaris. This is the first case that has IgG autoantibodies to all Dsc1~3.
Asunto(s)
Especificidad de Anticuerpos , Desmocolinas/inmunología , Inmunoglobulina G/inmunología , Enfermedades Cutáneas Vesiculoampollosas/inmunología , Comorbilidad , Desmogleína 1/inmunología , Humanos , Immunoblotting , Masculino , Persona de Mediana Edad , Pénfigo/inmunología , Enfermedades Cutáneas Vesiculoampollosas/epidemiología , Neoplasias Gástricas/epidemiologíaAsunto(s)
Inmunohistoquímica , Interleucina-17/análisis , Psoriasis/inmunología , Piel/inmunología , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Vitíligo/inmunología , Anciano , Biomarcadores/análisis , Biopsia , Femenino , Humanos , Valor Predictivo de las Pruebas , Psoriasis/patología , Piel/patología , Vitíligo/patologíaRESUMEN
Pulse corticosteroid therapy is effective for alopecia areata (AA) in the early stage. The risk and efficacy of this therapy for patients with several backgrounds, however, remains controversial. To explore the predictive factors of the response and risk factors of this therapy, data from 105 AA patients treated with methylprednisolone (500 mg) i.v. for 3 days consecutively in our facility were retrospectively analyzed. Among good responders, longer time from the onset to therapy was correlated with longer time required for hair regrowth (P = 0.037, n = 27). Multivariate models demonstrated that "severity", "relapse" and longer "duration from the latest onset" were significantly and independently associated with poorer outcome (P < 0.01). "History of atopic dermatitis (AD)" was also associated with poorer outcome, but this correlation could be explained by the effect that duration from the latest onset of AA was longer among participants with AD. We propose that earlier initiation of pulse corticosteroid therapy is preferable for better outcome of AA, particularly among patients with AD. Clinicians should be mindful of the occurrence of mild adverse effects in the elderly patients.
Asunto(s)
Alopecia Areata/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Metilprednisolona/administración & dosificación , Adolescente , Adulto , Factores de Edad , Alopecia Areata/epidemiología , Comorbilidad , Dermatitis Atópica/epidemiología , Femenino , Estudios de Seguimiento , Glucocorticoides/efectos adversos , Humanos , Japón , Masculino , Metilprednisolona/efectos adversos , Persona de Mediana Edad , Pronóstico , Quimioterapia por Pulso/efectos adversos , Recurrencia , Estudios Retrospectivos , Factores de Tiempo , Tiempo de Tratamiento , Resultado del Tratamiento , Adulto JovenAsunto(s)
Síndrome de Secreción Inadecuada de ADH/etiología , Melanoma/complicaciones , Neoplasias Cutáneas/complicaciones , Anciano de 80 o más Años , Resultado Fatal , Femenino , Humanos , Síndrome de Secreción Inadecuada de ADH/diagnóstico , Melanoma/secundario , Metástasis de la Neoplasia , Neoplasias Cutáneas/patologíaAsunto(s)
Neoplasias de los Genitales Masculinos/patología , Enfermedad de Paget Extramamaria/patología , Biopsia del Ganglio Linfático Centinela , Neoplasias Cutáneas/patología , Anciano , Anciano de 80 o más Años , Neoplasias de los Genitales Masculinos/cirugía , Ingle , Humanos , Escisión del Ganglio Linfático , Metástasis Linfática , Masculino , Enfermedad de Paget Extramamaria/cirugía , Pene , Escroto , Neoplasias Cutáneas/cirugíaRESUMEN
Gamma-glutamyl carboxylase (GGCX) gene mutation causes GGCX syndrome (OMIM: 137167), which is characterized by pseudoxanthoma elasticum (PXE)-like symptoms and coagulation impairment. Here, we present a 55-year-old male with a novel homozygous deletion mutation, c.2,221delT, p.S741LfsX100, in the GGCX gene. Histopathological examination revealed calcium deposits in elastic fibers and vessel walls, and collagen accumulation in the mid-dermis. Studies of dermal fibroblasts from the patient (GGCX dermal fibroblasts) demonstrated that the mutated GGCX protein was larger, but its expression level and intracellular distribution were indistinguishable from those of the wild-type GGCX protein. Immunostaining and an enzyme-linked immunosorbent assay showed an increase in undercarboxylated matrix gamma-carboxyglutamic acid protein (ucMGP), a representative substrate of GGCX and a potent calcification inhibitor, indicating that mutated GGCX was enzymatically inactive. Under osteogenic conditions, calcium deposition was exclusively observed in GGCX dermal fibroblasts. Furthermore, GGCX dermal fibroblast cultures contained 23- and 7.7-fold more alkaline phosphatase (ALP)-positive cells than normal dermal fibroblast cultures (n = 3), without and with osteogenic induction, respectively. Expression and activity of ALP were higher in GGCX dermal fibroblasts than in normal dermal fibroblasts upon osteogenic induction. mRNA levels of other osteogenic markers were also higher in GGCX dermal fibroblasts than in normal dermal fibroblasts, which including bone morphogenetic protein 6, runt-related transcription factor 2, and periostin (POSTN) without osteogenic induction; and osterix, collagen type I alpha 2, and POSTN with osteogenic induction. Together, these data indicate that GGCX dermal fibroblasts trans-differentiate into the osteogenic lineage. This study proposes another mechanism underlying aberrant calcification in patients with GGCX syndrome.
Asunto(s)
Calcinosis/genética , Ligasas de Carbono-Carbono/genética , Dermis/patología , Fibroblastos/patología , Osteogénesis/genética , Regulación hacia Arriba/genética , Fosfatasa Alcalina/metabolismo , Biomarcadores/metabolismo , Proteínas Morfogenéticas Óseas/metabolismo , Calcinosis/patología , Proteínas de Unión al Calcio/metabolismo , Transdiferenciación Celular , Proteínas de la Matriz Extracelular/metabolismo , Eliminación de Gen , Homocigoto , Humanos , Espacio Intracelular/metabolismo , Masculino , Persona de Mediana Edad , Transporte de Proteínas , Seudoxantoma Elástico/enzimología , Seudoxantoma Elástico/patología , Transducción de Señal , Síndrome , Proteína Gla de la MatrizRESUMEN
Pseudoxanthoma elasticum (PXE) is a hereditary disease, causing calcification and degeneration of elastic fibers, which affects the skin, eye, cardiovascular systems and gastrointestinal tract. PXE is caused by mutations in the ABCC6 gene. Neither detailed nor large-scale analyses have been accomplished in Japanese patients with PXE. We, therefore, investigated clinical symptoms and ABCC6 gene mutations in 76 Japanese patients. Japanese PXE patients (n = 76) had a significantly lower incidence of vascular lesions than 505 PXE patients in the Leiden Open Variation Database (LOVD) (38.7% vs 65.1%, respectively; P = 1.34E-06); however, the incidences of the skin, eye, cardiac and gastrointestinal lesion symptoms were not significantly different. Symptom severity scores for skin, eye and vascular lesions, calculated using the Phenodex™ system, were significantly lower in Japanese PXE patients than in LOVD PXE patients. Genetic analysis revealed three nonsense, four frame-shift, one exon deletion and 13 missense mutations in ABCC6 in 73 patients; however, we were unable to detect pathogenic mutations in three patients. Frequent mutations differed between Japanese and LOVD PXE patients. In Japanese PXE patients, the top five mutations accounted for more than 60% of all pathogenic changes, suggesting the presence of founder effects. Consistent with previous reports, no obvious correlations between genotypes and phenotypes were identified in this study. In conclusion, we consider that the milder clinical phenotypes, observed even in older Japanese PXE patients, could be attributed to environmental factors such as dietary habits and lifestyle, as well as genetic background.